▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Cheryl Swanson

CherylSwanson

Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson

Recent Articles by Cheryl Swanson

Pills

Oct 16, 2018 by Cheryl Swanson

5 Largest Markets for Pharmaceuticals

The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for big pharma and big biotech players.

May 8, 2015 by Cheryl Swanson

Regeneron Earnings Shine, but All Eyes Are on the Pipeline

Regeneron topped estimates Thursday as Eylea sales continue to soar. But the stock failed to hold its gains, as all eyes appear to now be on the biotech's pipeline.

Apr 29, 2015 by Cheryl Swanson

Express Scripts Issues Upbeat Outlook Despite Shifting Competitive Landscape

As UnitedHealth gobbles up Catamaran, Express Scripts is now swimming with the sharks, so why isn't the PBM market leader flinching?

Apr 24, 2015 by Cheryl Swanson

Illumina's Earnings Set Positive Tone for Biotech

What's behind Illumina's remarkable earnings beat, and what could it mean for biotech stocks?

Apr 23, 2015 by Cheryl Swanson

5 Things UnitedHealth Wants You to Know

Does UnitedHealth's stock have more room to run? Here's what management had to say on trends that could make or break the nation's largest health insurer.

Apr 20, 2015 by Cheryl Swanson

UnitedHealth's Earnings Deliver, but Risks Lurk Beneath the Surface

Shares of UnitedHealth are up 50% over the past year, but three major problems lurk beneath the surface, including a coming landmark Supreme Court decision.

Cancercapture

Apr 5, 2015 by Cheryl Swanson

Disruptive Innovation Changing the Fight Against Cancer

After decades of false starts, new immunotherapies are achieving long-lasting remissions in patients with extremely deadly cancers. Some doctors are even daring to use the word "cure."

bestleap-from good to great

Apr 5, 2015 by Cheryl Swanson

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Mar 31, 2015 by Cheryl Swanson

The Single Worst Practice of the Drug Industry

Pay for delay is a legal maneuver Big Pharma uses to keep generic drugs off the market. According to the FTC, it costs consumers and taxpayers $3.5 billion every year.

Mar 23, 2015 by Cheryl Swanson

This Market Could Grow 6250% in 10 Years

With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.

000000000000creativecommonsmfmedicaldevices

Mar 22, 2015 by Cheryl Swanson

The Single Worst Practice of Medical Device Makers

Cutting-edge medical devices are revolutionizing the field of medicine, but there's a downside. Medical device companies that single-mindedly put profits before patients have been known to release products that can cause debilitating injuries.

0000acadia

Mar 19, 2015 by Cheryl Swanson

This Exciting Biotech Isn't Built to Last

Acadia Pharmaceuticals' Parkinson's disease drug was guaranteed a speedy review and the attention of top FDA officials. So why did this company's stock recently tank so rapidly? There's a cautionary tale here for all biotech investors.

Mar 17, 2015 by Cheryl Swanson

Where Is Radius Health Now?

I haven't bought high-flying Radius Health yet, but I'm watching it closely. With news due any day now on its innovative osteoporosis drug, Radius could be set to make another big move up.

Feb 16, 2015 by Cheryl Swanson

Deal-Hungry Pfizer Won't Stop With Hospira; Who Could Be Next?

Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.

Feb 4, 2015 by Cheryl Swanson

$4 Billion Opportunity: Pfizer inc. Snags Approval for Potential Blockbuster

Two months ahead of schedule, Pfizer's blockbuster Ibrance is headed for market. The first-in-class drug could well become the standard-of-care for a large group of advanced breast cancer patients.

Jan 9, 2015 by Cheryl Swanson

Diving Deeper into Biogen's Lingo Results

Biogen's nerve repair drug failed to clear some key hurdles in its clinical trial against an eye disease. But the company highlighted positive data that shows the drug could have potential in its much more important target, multiple sclerosis.

Dec 4, 2014 by Cheryl Swanson

1 Big FDA Decision I'm Watching This Month

Pivotal FDA decisions can either hammer a biotech or make investors rich almost overnight. But you have to know how to play them.

Dec 4, 2014 by Cheryl Swanson

Johnson & Johnson Bought Alios for Hepatitis C

Gilead Sciences leapfrogged in front of competitors when it snagged the game-changing "nuc" Solvadi from Pharmasset. Now J&J is taking a similar leap, paying $1.75 billion for some potent antivirals, including one that could someday fulfill an unmet medical need.

Oct 13, 2014 by Cheryl Swanson

CVS Health Corp.'s New Prescription for Growth

Rebranded CVS Health is teaming up with hospitals and doctors to change consumer behavior. Will the company's multiple health initiatives unlock more shareholder value?

Sep 30, 2014 by Cheryl Swanson

Gilead Sciences, Inc. Stock's Stunning New Opportunity

The biotech giant has spent over $1.2 billion to buy blood cancer drugs. And with Zydelig's recent approval, it looks like it's finally struck gold.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services